Skip to main content Skip to navigation

[University home]

School of Medicine

Professor Nigel Bundred MD, FRCS

Photograph of Nigel Bundred

Professor of Surgical Oncology

University Hospital of South Manchester
2nd Floor, Education and Research Centre
Southmoor Road
Manchester
M23 9LT

 

Role

My role as Professor of Surgical Oncology is principally based at the University Hospital of South Manchester NHS Foundation Trust, Wythenshawe Hospital and involves management of all types of breast disease as well as thyroid problems. I work 3 PAs in the Christie Hospital and have active laboratory research in the Paterson Institute for Cancer Research.

In September 2007 I was appointed as Clinical Lead for Research for the Greater Manchester and Cheshire Cancer Research Network and Clinical Director for the recently awarded Breakthrough Breast Cancer Unit.

 

Memberships of Committees and Professional Bodies

I am a member of the following societies/organisations:

  • Association of Surgeons of Great Britain and Ireland
  • British Association for Cancer Research
  • British Association of Surgical Oncology (BASO), Elected National Committee Member
  • British Breast Group
  • Clinical Trials Advisory Awards Committee, Cancer UK
  • European School of Surgical Oncology
  • National Cancer Research Network (NCRN), Trials Adoption Committee
  • National Institute for Health Research Senior Faculty Member
  • Society of Academic & Research Surgery (SARS), Elected National Committee Member

Research

My current research programme is concentrated on two main areas; breast cancer and parathyroid hormone related protein/hypercalcaemia of malignancy. I currently have a team of 2 research registrars, 2 postdoctoral assistants and 2 technicians working on various laboratory research areas. In addition 3 ½ research nurses and 1 graduate research worker are working on various clinical trials and studies for which I have obtained funding. In total nine MD theses and one PhD have been awarded under my supervision.

Active research areas encompass breast cancer prevention, mechanisms of bone metastasis, angiogenesis, stem cell (non-adherent) culture of DCIS and invasive breast cancer. Other areas of interest include endocrine therapy of breast cancer and tumour tissue analysis (microarray).

Ductal Carcinoma in Situ (DCIS)

DCIS constitutes 30% of all screen detected breast cancer. I have developed an athymic nude mouse model in which human DCIS is implanted as xenografts and survives up to two months, in collaboration with Professor Chris Potten in the Paterson Institute for Cancer Research.

More recently I have identified stem cells from DCIS lesions and demonstrated growth inhibition of non-adherent stem like cells by NOTCH and epidermal growth factor receptor inhibition.

Working with Dr Rob Clarke and Dr Gill Farnie in the Breast Biology Group, we have developed cancer stem cell culture from primary human DCIS and shown that DCIS stem cells are controlled by NOTCH and epidermal growth factor receptor. In addition, we have shown that inhibiting HER2 oncogene overexpressing DCIS cells leads to inhibition of proliferation, leading to development of clinical trials in this condition with anti-HER2 inhibitors.

 

Control of Apoptosis in the Normal Breast in Breast Cancer

We have developed studies on apoptosis in both normal breast, DCIS and invasive cancer (in collaboration with Professor Charles Streuli) where we investigated mechanisms of inducing or preventing apoptosis in the breast. We initially developed new measures of apoptosis (activated caspase3 immunohistochemistry) and more latterly we have investigated the role of inhibitors of apoptosis intracellular proteins which block apoptosis and are elevated in breast cancer.

More recently we have obtained a grant from Breast Cancer Campaign to study inhibitors of apoptosis proteins (IAPs). These proteins prevent the final execution of the cell and we are analysing which of the 8 proteins are over expressed in breast cancer and whether inhibiting individual IAPs will induce tumour response and an increase in apoptosis.

Stromal Influences on Breast Cancer Growth

Working with Prof. Goran Landberg, we have shown that the use of aromatase inhibitors switches off activated stroma in breast cancers in a randomised controlled trial and we are exploring ways of switching off both the stroma and epithelial cells simulataneously to augment response to therapy.

Prevention of Lymphoedema

A large, £1.5m, National Institute for Health Research Programme Grant has been obtained to study whether early detection of arm swelling by measurement or bioimpedance will allow prevention of progression to lymphoedema through the use of external compression garments. These latter studies are taking place at the Nightingale Breast Centre, a £14m new building concentrating on the prevention and detection of breast cancer.  

 

 

Methodological Knowledge

  • "In Vivo" Models
  • Clinical Trials
  • Translational Science
 

Teaching

I have an undergraduate surgical firm (3rd year) and run Speciality Study Modules (SSM) for final year students and have been involved in teaching undergraduates and postgraduates since 1980.

I taught anatomy in Newcastle to medical, dental and physiotherapy students and in all the academic centres in which I have worked I have been involved in bedside and formal teaching of medical students.

I undertake regular ward and outpatient clinic teaching and act as an internal examiner for the University of Manchester. I am a Lecturer on the third year medical students Basic Integrated Science Course for Breast Disease and I also lecture on the introductory course teaching medical students Basic Clinical Skills.

 

Biography

I am a Professor of Surgical Oncology and Consultant Surgeon based at the University Hospital of South Manchester NHS Foundation Trust and the Christie Hospital in Manchester where I have a large clinical commitment to the Manchester Breast Service, which is the largest in the country. I graduated from Newcastle University in 1980 and was awarded my medical degree in 1990. After completing my training in Edinburgh, Leicester, Cardiff and Birmingham I joined the University of Manchester as a Senior Lecturer in Surgical Oncology in 1991, and was appointed as Professor of Surgical Oncology in 1999.

I have research interests in preinvasive cancer (ductal carcinoma in situ), breast cancer chemoprevention, endocrine therapy and bone metastases and I have developed xenograft models of human DCIS, primary culture and stem cell cultures of human DCIS. My research in Manchester was recognised by the Royal College of Surgeons of England when I was appointed a Hunterian Professorship in 1995 for my work on parathyroid hormone related peptide and its role in bone metastases. I am a member of numerous medical societies and have been the recipient of numerous honours and awards, including the Patey Prize from the Society of Academic & Research Surgery (SARS) and the Ronald Raven Prize from the British Association of Surgical Oncology (BASO).

I have authored or co-authored more than 160 peer-reviewed articles and my work has appeared in many journals, including the Journal of the National Cancer Institute, The Lancet, Cancer Research and Cancer. I am also the chief investigator on several preoperative DCIS trials and an international trial (DCIS II) funded by Cancer UK.

 

Qualifications

1990 MD Thesis, Newcastle University Medical School
1986 FRCS (England), Royal College of Surgeons
1985 FRCS (Edinburgh and Glasgow), Royal College of Surgeons
1975-1980 MB BS, Newcastle University Medical School
 

Publications

2011

  • Bundred NJ, Prasad R, Morris J, Knox WF, Byrne G, Cheung S, Wilson M, Lawrence G. (2011). Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)? Breast Cancer Res Treat, eScholarID:148048
  • Coleman RE, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M, Gil M, Houston SJ, Grieve RJ, Barrett-Lee PJ, Ritchie D, Pugh J, Gaunt C, Rea U, Peterson J, Davies C, Hiley V, Gregory W, Bell R; AZURE Investigators. (2011). Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med, 365(15), 1396-1405. eScholarID:148043 | DOI:10.1056/NEJMoa1105195
  • Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD. (2011). Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol, 12(1), 21-29. eScholarID:148053 | DOI:10.1016/S1470-2045(10)70266-7
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J, Gray R, Pierce L, Whelan T, Wang Y, Peto R. (2011). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet, 378(9804), 1707-1716. eScholarID:148039 | DOI:10.1016/S0140-6736(11)61629-2
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Davies C, Godwin J, Gray R, Clarke M, Cutter D, Darby S, McGale P, Pan HC, Taylor C, Wang YC, Dowsett M, Ingle J, Peto R. (2011). Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet, 378(9793), 771-784. eScholarID:148046
  • Hadji P, Aapro MS, Body JJ, Bundred NJ, Brufsky A, Coleman RE, Gnant M, Guise T, Lipton A. (2011). Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Ann Oncol, 22(12), 2546-2555. eScholarID:148051 | DOI:10.1093/annonc/mdr017

2010

  • Bundred NJ, Cramer A, Morris J, Renshaw L, Cheung KL, Flint P, Johnson R, Young O, Landberg G, Grassby S, Turner L, Baildam A, Barr L, Dixon JM. (2010). Cyclooxygenase-2 Inhibition Does Not Improve the Reduction in Ductal Carcinoma In situ Proliferation with Aromatase Inhibitor Therapy: Results of the ERISAC Randomized Placebo-Controlled Trial. Clinical Cancer Research, 16(5), 1605-1612. eScholarID:77636 | DOI:10.1158/1078-0432.CCR-09-1623
  • Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Correa C, McGale P, Taylor C, Wang Y, Clarke M, Davies C, Peto R, Bijker N, Solin L, Darby S. (2010). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr, 2010(41), 162-177. eScholarID:148171 | DOI:10.1093/jncimonographs/lgq039
  • Evans DG, Harvie M, Bundred N, Howell A. (2010). Uptake of breast cancer prevention and screening trials. J Med Genet, 47(12), 853-855. eScholarID:148162 | DOI:10.1136/jmg.2010.082768
  • Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ, Clarke RB. (2010). Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Research, 70(2), 709-718. eScholarID:77637 | DOI:10.1158/0008-5472.CAN-09-1681

2009

  • Association of Breast Surgery at BASO. (2009). Surgical guidelines for the management of breast cancer. Eur J Surg Oncol, 35(Supple. 1), 1-22. eScholarID:148173
  • Bundred NJ. (2009). Aromatase inhibitors and bone health. Curr Opin Obstet Gynecol, 21( 1), eScholarID:1d32543 | DOI:10.1097/GCO.0b013e32831da80e
  • Foster FM, Owens TW, Tanianis-Hughes J, Clarke RB, Brennan K, Bundred NJ, Streuli CH. (2009). Targeting inhibitor of apoptosis proteins in combination with ErbB antagonists in breast cancer. Breast Cancer Research, 11(3), R41. eScholarID:77638 | DOI:10.1186/bcr2328
  • Kenemans P, Bundred NJ, Foidart JM, Kubista E, von Schoultz B, Sismondi P, Vassilopoulou-Sellin R, Yip CH, Egberts J, Mol-Arts M, Mulder R, van Os S, Beckmann MW; LIBERATE Study Group. (2009). Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol, 10(2), 135-146. eScholarID:148176 | DOI:10.1016/S1470-2045(08)70341-3
  • Kenemans, P, Bundred, NJ, Foidart, J, Kubista, E, von Schoultz, B, Sismondi, P, Vassilopoulou-Sellin, R, Yip, C, Egberts, J, Mol-Arts, M, Mulder, R, van Os, S, Beckmann, M, NULL. (2009). Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol, 10( 2), eScholarID:1d32645 | DOI:10.1016/S1470-2045(08)70341-3

2008

  • Brufsky, A, Bundred, NJ, Coleman, R, Lambert-Falls, R, Mena, R, Hadji, P, Jin, L, Schenk, N, Ericson, S, Perez, E, NULL. (2008). Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist, 13(5), 503-514. eScholarID:1d32646 | DOI:10.1634/theoncologist.2007-0206
  • Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE. (2008). Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer, 112(5), 1001-1010. eScholarID:148178 | DOI:10.1002/cncr.23259
  • Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE. (2008). Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results. Cancer, 112(5), 1001-1010. eScholarID:77640 | DOI:10.1002/cncr.23259

2007

  • Byrne G, Hayden K, McDowell G, Lang H, Kirwan C, Tetlow L, Kumar S, Bundred NJ. (2007). Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. Int J Oncol, 31(5), 1127-1132. eScholarID:1d32428
  • Byrne G, McDowell G, Agarawal R, Sinha G, Kumar S, Bundred NJ. (2007). Serum vascular endothelial growth factor in breast cancer. Anticancer Research, 27(5B), 3481-3487. eScholarID:1d32648
  • Byrne GJ, Hayden KE, McDowell G, Lang H, Kirwan CC, Tetlow L, Kumar S, Bundred NJ. (2007). Angiogenic characteristics of circulating and tumoural thrombospondin-1 in breast cancer. Int J Oncol, 31(5), 1127-1132. eScholarID:148187
  • Byrne GJ, McDowell G, Agarawal R, Sinha G, Kumar S, Bundred NJ. (2007). Serum vascular endothelial growth factor in breast cancer. Anticancer Res, 27(5B), 3481-3487. eScholarID:148181
  • Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K, Anderson N, Bundred NJ. (2007). Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst, 99(8), 616-627. eScholarID:1d15720 | DOI:10.1093/jnci/djk133
  • Lavelle K, Moran A, Howell A, Bundred NJ, Campbell M, Todd C. (2007). Older women with operable breast cancer are less likely to have surgery. Br J Surg, 94(10), 1209-1215. eScholarID:1d31614
  • Lavelle KJ, Todd C, Moran A, Howell A-, Bundred NJ, Campbell MG. (2007). Non-standard management of breast cancer increases with age in the UK: a population based cohort of women >65 years. British Journal Of Cancer, 96(8), 1197-1203. eScholarID:1d27639 | DOI:10.1038/sj.bjc.6603709
  • Patiar S, Kirwan C, McDowell G, Bundred NJ, McCollum CN, Byrne GJ. (2007). Prevention of venous thromboembolism in surgical patients with breast cancer. Br J Surg, 94(4), 412-420. eScholarID:1d17262

2006

  • Al-Khaffaf BH, Shanks JH, Bundred N. (2006). Erythema nodosum--an extramammary manifestation of granulomatous mastitis. Breast J, 12(6), 569-570. eScholarID:148188
  • Barnes N, Haywood P, Flint P, Knox WF, Bundred NJ. (2006). Survivin expression in in situ and invasive breast cancer relates to COX-2 expression and DCIS recurrence. Br J Cancer, 94(2), 253-258. eScholarID:148220
  • Bundred N. (2006). The evolving role of exemestane in the management of breast cancer. Br J Hosp Med, 67(8), 427-430. eScholarID:148196
  • Bundred NJ. (2006). 35.Letrozole: a well-tolerated and effective treatment for breast cancer. Womens Health, 2(5), 673-685. eScholarID:148193
  • Dixon JM, Bundred N. (2006). Aromatase inhibitors for early breast cancer therapy: a choice of effective treatment strategies. Eur J Surg Oncol, 32(2), 123-125. eScholarID:148222
  • Kirwan C, McCollum CN, Bundred NJ, Byrne GJ. (2006). Current UK practice of thromboprophylaxis for breast surgery. Br J Surg, 93( 10), eScholarID:1d17259
  • Mansel RE, Fallowfield L, Kissin M, Goyal A, Newcombe RG, Dixon JM, Yiangou C, Horgan K, Bundred N, Monypenny I, England D, Sibbering M, Abdullah TI, Barr L, Chetty U, Sinnett DH, Fleissig A, Clarke D, Ell PJ. (2006). Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst, 98(9), 599-609. eScholarID:148197
  • Wärnberg F, White D, Anderson E, Knox F, Clarke RB, Morris J, Bundred NJ. (2006). Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo. Breast Cancer Res, 8(2), eScholarID:148206

2005

  • Barnes N, Khavari S, Boland G, Cramer A, Knox W, Bundred NJ. (2005). Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res, 11( 6), 2163-8. eScholarID:1d11256 | DOI:10.1158/1078-0432.CCR-04-1633
  • Bundred N. (2005). Breast pain. Clin Evid, (14), 2190-2199. eScholarID:148203
  • Bundred N. (2005). Preclinical and clinical experience with fulvestrant (Faslodex) in postmenopausal women with hormone receptor-positive advanced breast cancer. Cancer Invest, 23(2), 173-181. eScholarID:148228
  • Bundred NJ, Barnes N. (2005). Potential use of COX-2-aromatase inhibitor combinations in breast cancer. Br J Cancer, 93 Suppl 1, S10-5. eScholarID:1d29605
  • Kroiss R, Fentiman IS, Helmond FA, Rymer J, Foidart JM, Bundred N, Mol-Arts M, Kubista E. (2005). The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. BJOG, 112(2), 228-233. eScholarID:148234
  • McDowell G, Temple I, Li C, Kirwan CC, Bundred NJ, McCollum CN, Burton IE, Kumar S, Byrne GJ. (2005). Alteration in platelet function in patients with early breast cancer. Anticancer Res, 25(6B), 3963-3966. eScholarID:148226

2004

  • Boland G, Butt I, Prasad R, Knox W, Bundred NJ. (2004). COX-2 expression is associated with an aggressive phenotype in ductal carcinoma in situ. Br J Cancer, 90( 2), 423-9. eScholarID:1d29172
  • Bundred NJ. (2004). Breast cancer and HRT use. Maturitas, 49( 1), S3-4. eScholarID:1d29333

2003

  • Bundred NJ, Morris J. (2003). Breast cancer and hormone-replacement therapy: the Million Women Study. Lancet, 362( 9392), 1329; author reply 1330-1. eScholarID:1d28802
  • Hoey R, Sanderson C, Iddon J, Brady G, Bundred NJ, Anderson N. (2003). The parathyroid hormone-related protein receptor is expressed in breast cancer bone metastases and promotes autocrine proliferation in breast carcinoma cells. Br J Cancer, 88( 4), 567-73. eScholarID:1d29555
  • Prasad R, Boland G, Cramer A, Anderson E, Knox W, Bundred NJ. (2003). Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma. Cancer, 98( 12), 2539-46. eScholarID:1d9552 | DOI:10.1002/cncr.11836

2002

  • Chan K, Knox W, Gee J, Morris J, Nicholson R, Potten C, Bundred NJ. (2002). Effect of epidermal growth factor receptor tyrosine kinase inhibition on epithelial proliferation in normal and premalignant breast. Cancer Res, 62( 1), 122-8. eScholarID:1d9553
  • Dey, P, Bundred, NJ, Gibbs, A, Hopwood, P, Baildam, A, Boggis, C, James, M, Knox, F, Leidecker, V, Woodman, C. (2002). Costs and benefits of a one stop clinic compared with a dedicated breast clinic: randomised controlled trial. BMJ, 324( 7336), eScholarID:1d9570 | DOI:10.1136/bmj.324.7336.507
  • Gilmore AA, Valentijn AA.J, Wang P, Ranger AM, Bundred NJ, O'Hare MJ, Wakeling A, Korsmeyer SJ, Streuli CC.H. (2002). Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor. J Biol Chem, 277, 27643-50. eScholarID:1d2749
  • Hoey R. Nolan T. Downey S. Brady G. Ashcroft L, R Linforth, Anderson NG, Bundred NJ. (2002). Co-expression of parathyroid hormone related protein and its receptor in early breast cancer predicts poor patient survival. Clin. Cancer Res, eScholarID:1d1998

2001

  • Ahmad T. Chan K. Dobson R, Anderson NG, Bundred NJ. (2001). ZD1839 (Iressa), a novel EGFR tyrosine kinase inhibitor, inhibits the growth of EGFR expressing cell lines with or without erbB overexpression. Int J Cancer, 94, 774-782. eScholarID:1d1995
  • Chan KC, Knox WF, Sinha G, Gandhi A, Barr L, Baildam AD, Bundred NJ. (2001). Extent of excision margin width required in breast conserving surgery for ductal carcinoma in situ. Cancer, 91, 9-16. eScholarID:1d2731
  • Hadjiloucas I, Gilmore AA, Bundred NJ, Streuli CC.H. (2001). Assessment of apoptosis in human breast tissue using an antibody against the active form of caspase 3: relation to tumour histopathological characteristics. Br J Cancer, 85, 1522-6. eScholarID:1d2748

2000

  • Byrne GJ, Bundred NJ. (2000). Surrogate markers of tumoral angiogenesis. Int J Biol Markers, 15, eScholarID:1d2727
  • Byrne GJ, Ghellal A, Iddon J, Blann AD, Venizelos V, Kumar S, Howell A-, Bundred NJ. (2000). Serum soluble vascular cell adhesion molecule-1: Role as a surrogate marker of angiogenesis. J Natl Cancer Inst, 92, eScholarID:1d2662
  • Gandhi A, Holland P, Knox WF, Potten CS, Bundred NJ. (2000). Effects of pure antioestrogen on apoptosis and proliferation within human breast ductal carcinoma in situ (DCIS). Cancer Res, 4284-4288. eScholarID:1d2722
  • Ghellal A, Li C, Hayes M, Byrne GJ, Bundred NJ, Kumar S. (2000). Prognostic significance of TGF beta 1 and TGF beta 3 in human breast carcinoma. Anticancer Res, 20, eScholarID:1d2723
  • Hayden K, Tetlow L, Byrne GJ, Bundred NJ. (2000). Radioimmunoassay for the measurement of thrombospondin in plasma and breast cyst fluid: validation and clinical application. Ann Clin Biochem, 37, eScholarID:1d2754
  • Iddon J, Hoyland JA, Downey SE, McMahon R, Baird P, Salter D, Bundred NJ. (2000). Expression of parathyroid hormone-related protein and its receptor in bones metastases from prostrate cancer. J Pathol, 191, 170-174. eScholarID:1d2719
  • Li C, Guo B, Wilson PB, Stewart A, Byrne GJ, Bundred NJ, Kumar S. (2000). Plasma levels of soluble CD105 correlate with metastasis in patients with breast cancer. Int J Cancer, 89, eScholarID:1d2721

1999

  • Iddon J, Byrne GJ, Bundred NJ. (1999). Bone metastasis in breast cancer: the role of parathyroid hormone related protein. J Surg Oncol, 8, eScholarID:1d2713
  • Kumar S, Ghellal A, Cheng L, Byrne GJ, Haboubi N, Wang J, Bundred NJ. (1999). Breast carcinoma: vascular density determined using CD105 antibody correlates with tumour prognosis. Cancer Research, 59, eScholarID:1d2711

1998

  • Bramley M, Byrne GJ, Bundred NJ. (1998). Satisfaction with nurse specialists in breast care clinics. Nurses are not as effective as consultants. BMJ, 317, eScholarID:1d2757

  • Barnes NLP, Ooi JL, Yarnold JR, Bundred NJ. (In-press). Ductal Carcinoma in Situ (DCIS) of the breast. British Medical Journal, eScholarID:149935
  • Bundred NJ, Kenemans P, Yip CH, Beckmann MW, Foidart JM, Sismondi P, von Schoultz B, Vassilopoulou-Sellin R, El Galta R, van Lieshout E, Mol-Arts M, Planellas J, Kubista E. (In-press). Tibolone increases bone mineral density but also relapse in breast cancer survivors: LIBERATE Trial Bone Sub-study. Breast Cancer Research, eScholarID:149938

Top of page

| Skip to main content | Skip to navigation | Skip to Search |